GAITHERSBURG, Md., Oct. 9 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced that a resale registration statement has been
filed on Form S-3 with the Securities and Exchange Commission in connection
with its recent sale of $575 million principal amount of 1.375% Convertible
Senior Notes due 2011 and $575 million principal amount of 1.625% Convertible
Senior Notes due 2013. The registration statement became effective
automatically upon filing. The sale of $1.15 billion notes to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of 1933,
as amended (the "Securities Act"), was completed in June 2006. A copy of the
prospectus relating to the notes can be found on the Securities and Exchange
This press release does not constitute an offer to sell or a solicitation
of an offer to buy securities, nor shall there be any sale of the securities
in any state in which such offer, solicitation or sale would be unlawful prior
to registration or qualification of the securities under the securities laws
of any such state.
SOURCE MedImmune, Inc.
CONTACT: Investors: Peter Vozzo, +1-301-398-4358, or Media: Kate
Barrett, +1-301-398-4320, both of MedImmune, Inc.